{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-002718","form_type":"8-K","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.502452+00:00","generated_at":"2026-05-24T05:15:51.752518+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025","bullets":["Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.","ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager developed under a strategic partnership with Celltrion.","Data are under embargo until presentation; no results disclosed.","Presenter: Adam J. Pelzek, Ph.D., Associate Director at Abpro."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-002718","json":"https://secwatch.observer/filing/0001013762-25-002718.json","markdown":"https://secwatch.observer/filing/0001013762-25-002718.md","text":"https://secwatch.observer/filing/0001013762-25-002718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/0001013762-25-002718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000101376225002718/ea023575401-8k_abpro.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:15:51.752518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}